RxDoctor Payments Data

Sandra Richman

Internal Medicine · Brookline, MANPI 1023152717

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $885,955 of the $1,431,099 with a category attached, or 61.9%. Blueprint Medicines Corporation accounts for 61.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $374,598 and has fallen 76.9% since, to $86,469 in 2025. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,431,099in general payments, 2019–2025

Across 121 payments — averaging $11,827 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Blueprint Medicines Corporation$886K
  • Apellis Pharmaceuticals, Inc.$451K
  • Agios Pharmaceuticals, Inc.$57K
  • Sanofi$37K

What the payments were for

  • Consulting fees$545,14438%
  • Speaking & faculty fees$885,95562%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,431,099 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts →

Other internal medicine in Brookline

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →